Cytomegalovirus vaccine

A Cytomegalovirus vaccine is a vaccine against cytomegalovirus (CMV); such a vaccine is currently under investigation.^[1][2]

As a member of the TORCH complex, cytomegalovirus can cause congenital infection. Because of this, there has been considerable effort made towards the development of a vaccine, with particular emphasis on protection for pregnant women.^[3] (Cytomegalovirus also has a major impact upon individuals with acquired or induced immune deficiency,^[4] but because vaccination of the immunocompromised introduces additional challenges, members of this population are less likely to be candidates for such a vaccine.)

Development of such a vaccine has been emphasized as a priority by the National Vaccine Program Office in the United States.^[5][6]

recDB has been suggested as a target.^[7]

A phase 2 study of a CMV-vaccine published in 2009 indicated an efficacy of 50%, - thus the protection provided was limited and a number of subjects contracted CMV infection despite the vaccination. In one case also congenital CMV was encountered.^[8]

References

1. ^ Zhong J, Khanna R (June 2007). "Vaccine strategies against human cytomegalovirus infection". Expert Rev Anti Infect Ther 5 (3): 449–59. doi:10.1586/14787210.5.3.449. PMID 17547509. http://www.future-drugs.com/doi/abs/10.1586/14787210.5.3.449?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov. 
2. ^ Zhong J, Rist M, Cooper L, Smith C, Khanna R (2008). "Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus". PLoS ONE 3 (9): e3256. doi:10.1371/journal.pone.0003256. PMC 2533118. PMID 18806877. http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003256. 
3. ^ Schleiss MR (March 2008). "Comparison of vaccine strategies against congenital CMV infection in the guinea pig model". J. Clin. Virol. 41 (3): 224–30. doi:10.1016/j.jcv.2007.10.008. PMID 18060834. http://linkinghub.elsevier.com/retrieve/pii/S1386-6532(07)00362-9. 
4. ^ Schleiss MR, Heineman TC (June 2005). "Progress toward an elusive goal: current status of cytomegalovirus vaccines". Expert Rev Vaccines 4 (3): 381–406. doi:10.1586/14760584.4.3.381. PMID 16026251. http://www.future-drugs.com/doi/abs/10.1586/14760584.4.3.381?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov. 
5. ^ Khanna R, Diamond DJ (January 2006). "Human cytomegalovirus vaccine: time to look for alternative options". Trends Mol Med 12 (1): 26–33. doi:10.1016/j.molmed.2005.11.006. PMID 16337831. http://linkinghub.elsevier.com/retrieve/pii/S1471-4914(05)00266-2. 
6. ^ Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R (July 2004). "Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee". Clin. Infect. Dis. 39 (2): 233–9. doi:10.1086/421999. PMID 15307033. http://www.journals.uchicago.edu/cgi-bin/resolve?CID32962. 
7. ^ Mersseman V, Böhm V, Holtappels R, et al. (June 2008). "Refinement of strategies for the development of a human cytomegalovirus dense body vaccine". Med. Microbiol. Immunol. 197 (2): 97–107. doi:10.1007/s00430-008-0085-2. PMID 18320219. 
8. ^ Pass RF, Zhang C, Evans A, et al (2009). "Vaccine prevention of maternal cytomegalovirus infection". N Engl J Med 360 (12): 1191–9. doi:10.1056/NEJMoa0804749. PMC 2753425. PMID 19297572. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2753425.